Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 5/20 | 0.31 |
| ▸ | SGK1 | O00141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301962 | 0.87 | CDK2 (0.33) | MAPKAPK2GABRG2GABRB3GABRA5ALDH1A1 | |
| SCHEMBL6299627 | 0.87 | BRD4 (0.39) | ALDH1A1MAPTNPSR1BRD4 | |
| SCHEMBL6307281 | 0.85 | GABRG2 (0.32) | GABRG2GABRB3GABRA5BRD4 | |
| SCHEMBL6307252 | 0.85 | GABRG2 (0.31) | GABRG2GABRB3GABRA5BRD4 | |
| SCHEMBL6957144 | 0.84 | MAOA (0.37) | BRD4 | |
| SCHEMBL6301031 | 0.84 | KDM4E (0.33) | GABRG2GABRB3GABRA5ALDH1A1MAPT | |
| SCHEMBL6301321 | 0.82 | LTB4R (0.32) | GABRG2GABRB3GABRA5BRD4 | |
| SCHEMBL6300176 | 0.81 | BRD4 (0.36) | ALDH1A1BRD4 | |
| SCHEMBL6307052 | 0.80 | BRD4 (0.37) | BRD4 | |
| SCHEMBL6700648 | 0.80 | LTB4R (0.36) | GABRG2GABRB3GABRA5BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | claimed |
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | MAPKAPK2 1060/4885GABRG2 4570/4885GABRB3 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.